C
Cellivery Therapeutics Inc
KOSDAQ:268600
Cellivery Therapeutics Inc
KOSDAQ:268600
Price:
6 680
KRW
-29.91%
Market Closed
Market Cap:
₩594.9m
Balance Sheet
Balance Sheet Decomposition
Cellivery Therapeutics Inc
Cellivery Therapeutics Inc
Balance Sheet Decomposition is not available for
Cellivery Therapeutics Inc
Cellivery Therapeutics Inc
Balance Sheet
Cellivery Therapeutics Inc
Cellivery Therapeutics Inc
Currency: KRW
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
1 125
|
85
|
3 471
|
983
|
1 245
|
28 679
|
1
|
14 578
|
1 459
|
|
| Cash |
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
1 459
|
|
| Cash Equivalents |
1 125
|
85
|
3 470
|
983
|
1 245
|
28 679
|
0
|
14 578
|
0
|
|
| Short-Term Investments |
1 500
|
0
|
2 550
|
35 846
|
26 138
|
25 135
|
15 744
|
50
|
0
|
|
| Total Receivables |
9
|
124
|
320
|
661
|
553
|
301
|
5 538
|
6 811
|
3 242
|
|
| Accounts Receivables |
0
|
105
|
119
|
539
|
377
|
0
|
4 695
|
4 476
|
1 193
|
|
| Other Receivables |
0
|
19
|
201
|
122
|
176
|
0
|
843
|
2 334
|
2 049
|
|
| Inventory |
0
|
43
|
153
|
59
|
0
|
0
|
3 920
|
6 539
|
2 924
|
|
| Other Current Assets |
83
|
52
|
293
|
92
|
429
|
543
|
3 858
|
1 581
|
223
|
|
| Total Current Assets |
2 717
|
303
|
6 786
|
37 641
|
28 364
|
54 658
|
98 385
|
29 558
|
7 847
|
|
| PP&E Net |
1 020
|
1 350
|
1 290
|
1 436
|
1 587
|
2 705
|
24 130
|
39 064
|
19 487
|
|
| PP&E Gross |
0
|
0
|
1 290
|
1 436
|
1 587
|
2 705
|
24 130
|
39 064
|
19 487
|
|
| Accumulated Depreciation |
0
|
0
|
875
|
1 368
|
2 322
|
2 642
|
11 665
|
14 133
|
18 702
|
|
| Intangible Assets |
10
|
144
|
27
|
36
|
292
|
545
|
2 931
|
844
|
472
|
|
| Note Receivable |
259
|
247
|
0
|
277
|
0
|
282
|
883
|
11 701
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
1 970
|
3 124
|
3 052
|
1 135
|
|
| Other Long-Term Assets |
34
|
161
|
329
|
606
|
615
|
357
|
388
|
485
|
1 221
|
|
| Total Assets |
4 041
N/A
|
2 205
-45%
|
8 433
+282%
|
39 995
+374%
|
30 858
-23%
|
60 516
+96%
|
129 841
+115%
|
84 705
-35%
|
30 164
-64%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
2 209
|
1 225
|
261
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5 301
|
|
| Short-Term Debt |
100
|
57
|
0
|
0
|
0
|
0
|
9 114
|
14 071
|
16 524
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
5 483
|
0
|
167
|
362
|
11 833
|
30 149
|
28 947
|
|
| Other Current Liabilities |
8 471
|
22 194
|
23 709
|
3 393
|
1 916
|
899
|
2 991
|
9 678
|
3 592
|
|
| Total Current Liabilities |
8 571
|
22 251
|
29 192
|
3 393
|
2 084
|
1 261
|
26 147
|
55 123
|
54 625
|
|
| Long-Term Debt |
4 449
|
6 586
|
6 686
|
0
|
0
|
20 721
|
23 639
|
18 539
|
748
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
231
|
1 698
|
|
| Other Liabilities |
158
|
320
|
559
|
777
|
1 491
|
141
|
5 049
|
588
|
958
|
|
| Total Liabilities |
13 178
N/A
|
29 157
+121%
|
36 438
+25%
|
4 170
-89%
|
3 575
-14%
|
22 123
+519%
|
54 834
+148%
|
74 019
+35%
|
54 633
-26%
|
|
| Equity | ||||||||||
| Common Stock |
683
|
1 367
|
1 849
|
3 806
|
3 910
|
4 207
|
9 026
|
18 342
|
18 396
|
|
| Retained Earnings |
10 237
|
28 069
|
43 059
|
50 354
|
70 262
|
87 511
|
115 446
|
190 605
|
223 176
|
|
| Additional Paid In Capital |
417
|
267
|
13 204
|
82 373
|
93 636
|
121 698
|
172 026
|
168 006
|
169 953
|
|
| Other Equity |
0
|
17
|
0
|
0
|
0
|
0
|
9 402
|
14 943
|
10 358
|
|
| Total Equity |
9 137
N/A
|
26 952
-195%
|
28 005
-4%
|
35 826
N/A
|
27 283
-24%
|
38 393
+41%
|
75 007
+95%
|
10 686
-86%
|
24 469
N/A
|
|
| Total Liabilities & Equity |
4 041
N/A
|
2 205
-45%
|
8 433
+282%
|
39 995
+374%
|
30 858
-23%
|
60 516
+96%
|
129 841
+115%
|
84 705
-35%
|
30 164
-64%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
5
|
5
|
7
|
15
|
16
|
17
|
35
|
36
|
37
|
|
| Preferred Shares Outstanding |
3
|
3
|
2
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
